SCHEMBL3486780

SCHEMBL3486780

CONc1nc(-c2ccccc2)c2cc(Cl)ccc2n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.68
GAA P10253 4/20 0.68
TP53 P04637 1/20 0.65
MAT2A P31153 1/20 0.64
ADORA1 P30542 2/20 0.63
SMN1; SMN2 Q16637 3/20 0.61
ALDH1A1 P00352 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
KDM4E B2RXH2 4/20 0.57
THRB P10828 1/20 0.55
MAPK1 P28482 1/20 0.54
LMNA P02545 3/20 0.54
HPGD P15428 1/20 0.54
HTT P42858 1/20 0.54
POLB P06746 2/20 0.51
KMT2A Q03164 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11704650 0.81 MAPT (1.00) MAPTGAATP53MAT2AADORA1
SCHEMBL3487204 0.81 MAPT (0.68) MAPTGAATP53MAT2AADORA1
SCHEMBL11436371 0.80 ALDH1A1 (0.63) MAPTGAATP53MAT2AADORA1
SCHEMBL15840764 0.80 ADORA1 (0.83) MAPTGAATP53MAT2AADORA1
SCHEMBL11705840 0.79 POLB (0.74) MAPTGAATP53MAT2AADORA1
SCHEMBL5223547 0.79 TP53 (0.72) MAPTGAATP53MAT2AADORA1
SCHEMBL11706250 0.78 MAPT (0.65) MAPTGAATP53MAT2AADORA1
SCHEMBL24109317 0.78 MAT2A (0.61) MAPTGAATP53MAT2AADORA1
SCHEMBL7027700 0.76 MAPT (0.62) MAPTGAATP53MAT2AADORA1
SCHEMBL11707237 0.76 GAA (0.69) MAPTGAATP53MAT2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2100507-B1 QUINAZOLINE DERIVATIVES CAPABLE OF INHIBITING CYTOKININ SIGNALING SUMITOMO CHEMICAL CO (JP) 2015-02-25 EP disclosed
US-8722580-B2 Agent for inhibiting cytokinin signaling SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-05-13 US disclosed
US-20100056377-A1 AGENT FOR INHIBITING CYTOKININ SIGNALING SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-04 US disclosed
CN-101588716-A Substance capable of inhibiting cytokinin signaling SUMITOMO CHEMICAL CO (JP) 2009-11-25 CN disclosed
EP-2100507-A1 SUBSTANCE CAPABLE OF INHIBITING CYTOKININ SIGNALING Sumitomo Chemical Company, Limited (JP) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056377-A1 AGENT FOR INHIBITING CYTOKININ SIGNALING CROCC, STAT3, GRK6 MAPT 4826/4885GAA 3573/4885TP53 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.